Related Experiment Video
Updated: Jun 23, 2026
09:10
Heterotopic and Orthotopic Tracheal Transplantation in Mice used as Models to Study the Development of Obliterative Airway Disease
Published on: January 20, 2010
14.0K
Engineered Anti-Senescence Trachea With Post-Transplanted Regenerative Homeostasis
Ziyin Pan1,2, Hai Tang1,2, Lanlan Wang3
1Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China.
Summary
Engineered trachea implants face dysfunction due to tissue aging. A novel Hebe engineered trachea (Hebe-ET) uses dual anti-senescence designs to maintain regenerative homeostasis and improve transplant success.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Tissue Engineering
Background:
- Post-transplant dysfunction is a major hurdle in bioengineered complex organ development.
- Tissue senescence, poor cell contact, and immune dysregulation contribute to engineered trachea failure.
Purpose of the Study:
- To propose a novel engineered trachea with anti-senescence strategies to maintain regenerative homeostasis.
- To address key factors causing senescence in bioengineered tracheal constructs.
Main Methods:
- Development of a Hebe engineered trachea (Hebe-ET) with a ring-ring structure.
- Incorporation of a fiber-film scaffold in cartilage rings to enhance cellular contact.
- Integration of quercetin in fibrous connective tissue rings to scavenge oxidative stress and modulate immune response.
Main Results:
- Hebe-ET demonstrated sustained youthfulness and developed a natural-like structure with mature cartilage, vascular networks, and epithelium 12 weeks post-transplantation.
- The engineered trachea exhibited superior mechanical properties compared to native trachea.
- An 87.5% survival rate was observed in the animal models.
Conclusions:
- Anti-senescence design is crucial for fabricating successful complex organ substitutes.
- The Hebe-ET provides an effective engineering strategy for segmental trachea reconstruction, overcoming post-transplant dysfunction.
